Phamalimo SRL
0.8 FTEThe score of Phamalimo shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Change 2021 → 2024: Equity -91 % Total assets -38 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Phamalimo's annual accounts
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net result | −28,381 € | ||||
| Equity | 2,614 € | ||||
| Cash | 22,347 € | ||||
| EBITDA | −12,994 € | ||||
| Total assets | 159,435 € |
Filed annual accounts
- Year ended 31 Dec 2024filed on 27 Aug 2025
- Year ended 31 Dec 2023filed on 20 Jun 2024
- Year ended 31 Dec 2022filed on 05 Sep 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
- Year ended 31 Dec 2020filed on 12 Oct 2021
Phamalimo's financial analysis
- Solvency1.6%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Phamalimo
Phamalimo's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0846.675.386
- VAT number
- BE0846675386
- Peppol
- Registered · 0208:0846675386 · as of 05 Nov 2026
- Legal form
- SRL
- Incorporated
- 19 Jun 2012
- Registered office
- 7180 Seneffe
- Size
- Micro · 0.8 FTE
- Latest accounts
- 2024 · filed on 27 Aug 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Phamalimo (SRL) has been based in Seneffe since 2012, active in: retail sale of pharmaceutical products. For 2024, it reports a net loss of 28,381 € and equity of 2,614 €; its revenue is not published. With 0.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 1.6%, below the median of its sector (41.5%).
Companies similar to Phamalimo
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DE Bousval Retail sale of pharmaceutical products Genappe · balance sheet 139,616 €
- Apotheek Els De Smedt Retail sale of pharmaceutical products Beveren-Kruibeke-Zwijndrecht · balance sheet 157,911 €
- London Pharma Retail sale of pharmaceutical products Ixelles · balance sheet 161,051 €
- Monsoon Retail sale of pharmaceutical products Ghent · balance sheet 157,805 €
- Benoît Schleich Retail sale of pharmaceutical products Péruwelz · balance sheet 163,952 €
- Jovaphar Retail sale of pharmaceutical products Middelkerke · balance sheet 154,803 €
- By Nature Retail sale of pharmaceutical products Saint-Josse-ten-Noode · balance sheet 154,196 €
- Clement Pharma Services Retail sale of pharmaceutical products Meise · balance sheet 151,301 €
Frequently asked questions about Phamalimo
What is the revenue of Phamalimo?
Phamalimo files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Phamalimo?
In Belgium, the VAT number is the company number prefixed with BE: BE0846675386 for Phamalimo, if the company is VAT-registered. Its company number (CBE) is 0846.675.386.
Where is the registered office of Phamalimo?
According to the CBE register, the registered office of Phamalimo is in 7180 Seneffe.
What is the equity of Phamalimo?
At the close of the 2024 financial year, the equity of Phamalimo amounts to 2,614 €, a solvency of 1.6% of total assets.
How many people work at Phamalimo?
0.8 full-time equivalents on average according to the 2024 social balance sheet.
Who manages Phamalimo?
The register lists 2 active mandates at Phamalimo. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Phamalimo
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →